ART Pill Count and Clinical Outcomes in Treatment-Naive HIV ART Pill Count and Clinical Outcomes in Treatment-Naive HIV
Could a single-tablet ART regimen for HIV result in better outcomes over multiple-pill formulations?HIV Medicine
CONCLUSIONS: Thanks to a growing global network of GPP practitioners and a burgeoning GPP Community of Practice, there has been substantive progress in making GPP an integral component of clinical HIV prevention research. The Wits RHI experience highlights the possibilities and the challenges to translating the GPP principles into concrete practices within specific clinical trials and across a research institute. Realizing the full potential of GPP, including direct and indirect - 'collateral benefits' will require the collective buy-in and support from sponsors, implementers and community stakeholders across the research ...
CONCLUSIONS: HIV prevention is situated at the intersection of unprecedented opportunity and crisis. Person-centred approaches to HIV prevention and research shift power dynamics, and have the potential to ensure a more sustainable response with each individual actively participating in their own care and meaningfully contributing to the production of knowledge on HIV prevention. This approach taps into the resourcefulness, resilience and knowledge of the person and their communities, to strengthen research and programmes, making them more relevant, appropriate and effective. PMID: 30334609 [PubMed - in process]
It is not just about "the trial": the critical role of effective engagement and participatory practices for moving the HIV research field forward. J Int AIDS Soc. 2018 Oct;21 Suppl 7:e25179 Authors: MacQueen KM, Auerbach JD PMID: 30334608 [PubMed - in process]
CONCLUSIONS: As evidence-informed engagement strategies emerge, these should inform the ethics submission and review process. Both parties in the review process should strive to avoid a superficial, check-list type approach that caricatures what should be a thorough, nuanced ethics review of a rich, responsive engagement process. PMID: 30334604 [PubMed - in process]
CONCLUSIONS: Brief, targeted surveys of trial sites to characterize use of broad strategies, specific practices and some outcomes are a feasible option for evaluating good participatory practice. Additional testing is warranted to assess and enhance validity, reliability and predictive value of indicators. Options for collecting outcome measures through additional objective means should be explored. PMID: 30334601 [PubMed - in process]
Authors: Wheeler DP, Lucas J, Wilton L, Nelson LE, Hucks-Ortiz C, Watson CC, Hutchinson C, Mayer KH, Kuo I, Magnus M, Beauchamp G, Shoptaw S, Emel LM, Chen YQ, Hightow-Weidman L, Fields SD PMID: 30334600 [PubMed - in process]
CONCLUSIONS: We advocate for the integration of qualitative with clinical and survey research methods in pragmatic clinical and community-level trials and implementation studies, and for increasing visibility of qualitative and mixed methods research in medical journals. Qualitative research from trials ideally should be published along with clinical outcome data, either integrated into the "main" trial papers or published concurrently in the same journal issue. Integration of qualitative research within trials can help not only to understand the why behind success or failure of interventions in different context...
CONCLUSIONS: These results suggest that having strong community social resources will reduce AGYW's risk of HIV acquisition. Work to mobilize communities, focusing on building social cohesion, shared concerns, critical consciousness, and effective and accountable leadership, can fortify prevention programming for AGYW. PMID: 30334377 [PubMed - in process]
CONCLUSIONS: Our findings identify important directions for future stakeholder engagement research and suggestions for policy. Most notably, we found that stakeholder engagement was more frequently conducted to inform early stages of HIV clinical trials compared to later stages. In order to meet recommendations established in the GPP guidelines, greater stakeholder engagement across all clinical trial stages is needed. PMID: 30334358 [PubMed - in process]
No abstract available